FILE PHOTO: The logo of Grifols is seen during the 2018 shareholders meeting in their headquarters in Sant Cugat del Valles, near Barcelona, Spain May 25, 2018. REUTERS/Albert Gea
MADRID - Spanish pharmaceutical company Grifols said on Monday it agreed to buy plasma assets in North America from South Korea’s Green Cross for $460 million. Grifols will buy a plasma fractionation plant in Canada and two purification facilities and 11 plasma collection centres in the United States, the company said in a statement.Grifols is one of the world’s top producers of treatments based on human plasma.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: